Bain D F, Munday D L, Smith A
School of Pharmacy, Robert Gordon University, Aberdeen, UK.
J Microencapsul. 1999 May-Jun;16(3):369-85. doi: 10.1080/026520499289086.
Microspheres containing 20% w/w rifampicin (RIF) with smooth morphology have been readily prepared from combinations of low, R104 (Mw, 2000) and moderate, R202H (Mw, 9000), molecular weight poly(D,L-lactide) (PDLLA) as a means to modulate drug release from either polymer when used alone. These have been characterized with respect to their drug loading, granulometry, in vitro drug release and thermal behaviour. Particle size distributions were Gaussian, whereby mean microsphere diameter was found to increase from 2.11 to 2.98 microns as the proportion of more viscous R202H increased, whilst > 95% of particles were < 10 microns, irrespective of the polymer blend used. Use of a reduced inlet temperature for spray-drying gave uncharacteristically high production yields in the range of 55.8-80.7% for the process. Encapsulation efficiencies were quantitative with the weight proportion of drug co-dissolved (p < 0.05), yielding microspheres of high and predictable RIF loading. In vitro drug release revealed a dramatic shift in release profile between 40 and 60% R104. Closer examination in this range showed the predicted pattern of increased release rate as the fraction of more hydrophilic R104 increased. However, disproportionate differences were evident between 44 and 48% R104. From the apparent temperature dependent drug release, the criticality of matrix composition was attributed to the coincidence of matrix softening with the dissolution medium temperature and consequent hydration, which, at a finite composition, resulted in a controlled auto-hydration mechanism. Dramatic dependence of release rate with dissolution methodology was accountable to the fact that drug release was considerably quicker where microspheres remained suspended and individualized with the USP paddle method as opposed to aggregated with the shaking bath methodology. In conclusion, the utility of blending racemic PDLLA to modulate drug release and the convenience of spray-drying as a technique to produce microspheres of predictable character have been demonstrated. The temperature-dependent release exhibited may have application in the site-specific delivery of drugs where local increased biochemical activity promotes drug release in response to an increased pharmacological need.
通过低分子量的R104(Mw,2000)和中等分子量的R202H(Mw,9000)聚(D,L-丙交酯)(PDLLA)组合,已轻松制备出含有20%(w/w)利福平(RIF)且形态光滑的微球,以此作为单独使用时调节两种聚合物药物释放的一种手段。对这些微球的载药量、粒度分析、体外药物释放和热行为进行了表征。粒径分布呈高斯分布,随着更具粘性的R202H比例增加,平均微球直径从2.11微米增加到2.98微米,而无论使用何种聚合物共混物,超过95%的颗粒直径小于10微米。喷雾干燥时采用降低的进口温度,该工艺的产率异常高,在55.8 - 80.7%范围内。包封效率是定量的,药物共溶解的重量比例(p < 0.05),得到具有高且可预测RIF载药量的微球。体外药物释放显示,在R104含量为40%至60%之间,释放曲线发生了显著变化。在此范围内进一步研究表明,随着亲水性更强的R104比例增加,释放速率呈现出预测的增加模式。然而,在R104含量为44%至48%之间,差异明显不成比例。从明显依赖温度的药物释放来看,基质组成的关键作用归因于基质软化与溶解介质温度以及随之而来的水合作用的巧合,在有限的组成下,这导致了一种可控的自动水合机制。释放速率对溶解方法的显著依赖性可归因于这样一个事实,即与使用振荡浴方法使微球聚集相比,当微球通过美国药典桨法保持悬浮和个体化时,药物释放要快得多。总之,已证明外消旋PDLLA共混物在调节药物释放方面的实用性以及喷雾干燥作为一种生产具有可预测特性微球的技术的便利性。所表现出的温度依赖性释放可能在药物的定点递送中有应用,即局部生化活性增加时,根据药理学需求增加促进药物释放。